SSKN · As filed with the SEC

STRATA Skin Sciences balance sheet, by fiscal year

The statement as STRATA Skin Sciences presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.

Consolidated Balance Sheets · USD thousands

USD thousands	FY2025 Dec 31, 2025	FY2024 Dec 31, 2024	FY2023 Dec 31, 2023	FY2022 Dec 31, 2022	FY2021 Dec 31, 2021
Assets
Current assets:
Cash and cash equivalents	7,912	7,261	6,784	5,434	12,586
Restricted cash	0	1,334	1,334	1,361	0
Accounts receivable, net of allowance for credit losses of $551 and $433 at December 31, 2025 and 2024, respectively	4,121	5,253	4,440	4,471	3,433
Inventories	2,814	2,246	2,673	5,547	3,489
Prepaid expenses and other current assets	753	501	312	691	462
Total current assets	15,600	16,595	15,543	17,504	19,970
Property and equipment, net	8,964	10,061	11,778	7,498	6,883
Operating lease right-of-use assets	920	1,264	626	975	638
Intangible assets, net	3,377	5,348	7,319	17,394	10,083
Goodwill	1,429	2,658	6,519	8,803	8,803
Other assets	231	231	231	98	216
Total assets	30,521	36,157	42,016	52,272	46,593
Liabilities and Stockholders’ Equity
Current liabilities:
Current portion of long-term debt	15,349	—	—	—	—
Accounts payable	2,758	2,433	3,343	3,425	2,822
Accrued expenses and other current liabilities	6,155	8,593	6,306	6,555	6,377
Deferred revenues	2,248	2,241	2,120	2,778	3,285
Current portion of operating lease liabilities	231	328	352	355	318
Current portion of contingent consideration	0	1,030	53	313	0
Total current liabilities	26,741	14,625	12,174	13,426	12,802
Long-term debt, net	0	15,192	15,044	7,476	7,319
Deferred revenues and other liabilities	184	353	552	314	400
Deferred tax liability	—	0	186,000	306,000	266,000
Operating lease liabilities, net of current portion	688	919	237	610	392
Contingent consideration, net of current portion	0	96	1,135	8,309	0
Total liabilities	27,613	31,185	29,328	30,441	21,179
Stockholders’ equity:
Series C convertible preferred stock, $0.10 par value; 10,000,000 shares authorized, no shares issued and outstanding	0	0	0	0	0
Common stock, $0.001 par value; 150,000,000 shares authorized; 5,888,199 and 4,171,161 shares issued and outstanding at December 31, 2025 and 2024, respectively	6	4	35	35	34
Additional paid-in capital	257,307	253,112	250,711	249,024	247,059
Accumulated deficit	(254,405)	(248,144)	(238,058)	(227,228)	(221,679)
Total stockholders’ equity	2,908	4,972	12,688	21,831	25,414
Total liabilities and stockholders’ equity	30,521	36,157	42,016	52,272	46,593

As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.